Loading clinical trials...

COMPLETED

Metabolomic Analysis of Lung Cancer

Preoperative Metabolomic Analysis of Primary Lung Cancer: A Translational Clinical Trial of the Brown Cancer Center

NCT00263731•University of Louisville

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn more about the metabolic properties of lung cancer cells.

Detailed Description

It has long been known that cancer cells absorb and break down substances in the body differently than healthy, non-cancer cells. This process of absorbing and breaking down substances is known as metabolism and is increased in cancer cells. Recent research suggests that this increased metabolic activity makes it easier for cancer cells to multiply. The objective of the study is to characterize the metabolism of glucose by lung tumors by serum metabolite analysis, using a variant of glucose (sugar) which makes up 1% of glucose in nature.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Lung Cancer Patients (Groups 1 \& 2)
•patients with suspected, clinically diagnosed, or histologically diagnosed lung cancer. Occasionally, other cancers (including metastatic cancers to the lung) may be resected for the study as negative controls for NSCLC, as warranted by the particulars of the case.
•patients must have general medical conditions to allow them to undergo surgical resection of their primary tumor
•at least 30 years of age
•preferably be fasting for 12 hours (minimum 8 hours) prior to enrollment

Exclusion Criteria

•history of diabetes for the experimental group (surgery + glucose); patients with a history of diabetes are allowed in the control group (surgery/no glucose)
•known hepatitis C or HIV (AIDS)
•Healthy Subjects (Group 3)
•prior history of diagnosed lung cancer
•known hepatitis C or HIV (AIDS)

Locations (1)

James Graham Brown Cancer Center, University of Louisville

Louisville, Kentucky, United States

Key Dates

Start Date

December 1, 2005

Primary Completion Date

September 24, 2020

Completion Date

September 24, 2020

Last Updated

May 9, 2022

Enrollment

249

ACTUAL participants

Conditions

Carcinoma, Non-Small Cell LungCarcinoma, Small Cell Lung

Interventions

13-C-glucose

OTHER

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287

Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+4 more

View study

COMPLETEDPHASE1

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

NCT06549816

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and Neck+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Metabolomic Analysis of Lung Cancer

Inclusion Criteria

Exclusion Criteria

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma